tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Nail Diseases D009260 2 associated lipids
Paronychia D010304 3 associated lipids
Duodenal Ulcer D004381 12 associated lipids
Dyspnea D004417 10 associated lipids
Vascular Diseases D014652 16 associated lipids
Heart Defects, Congenital D006330 20 associated lipids
Listeriosis D008088 12 associated lipids
Connective Tissue Diseases D003240 2 associated lipids
Ascites D001201 25 associated lipids
Albuminuria D000419 18 associated lipids
Anemia D000740 21 associated lipids
Osteomalacia D010018 5 associated lipids
Tremor D014202 15 associated lipids
Pemphigoid, Bullous D010391 8 associated lipids
Vasculitis D014657 14 associated lipids
Hypothermia D007035 19 associated lipids
Parkinson Disease D010300 53 associated lipids
Down Syndrome D004314 18 associated lipids
Adrenal Insufficiency D000309 3 associated lipids
Keloid D007627 12 associated lipids
Nephritis D009393 19 associated lipids
Food Hypersensitivity D005512 7 associated lipids
Respiration Disorders D012120 5 associated lipids
Thymus Neoplasms D013953 15 associated lipids
Uterine Cervical Dysplasia D002578 2 associated lipids
Facial Neoplasms D005153 3 associated lipids
Dysgammaglobulinemia D004406 3 associated lipids
Influenza, Human D007251 11 associated lipids
Immune System Diseases D007154 3 associated lipids
Headache D006261 4 associated lipids
Cystitis D003556 23 associated lipids
Sarcoma, Kaposi D012514 6 associated lipids
HIV Infections D015658 20 associated lipids
Drug Eruptions D003875 30 associated lipids
Folliculitis D005499 7 associated lipids
Blindness D001766 6 associated lipids
Oliguria D009846 2 associated lipids
Dyskinesia, Drug-Induced D004409 15 associated lipids
Dermatitis, Allergic Contact D017449 20 associated lipids
Graves Disease D006111 6 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Gout D006073 4 associated lipids
Papillomavirus Infections D030361 4 associated lipids
Choline Deficiency D002796 16 associated lipids
Anemia, Hemolytic, Autoimmune D000744 5 associated lipids
Biliary Fistula D001658 13 associated lipids
Glomerulonephritis, Membranoproliferative D015432 3 associated lipids
Glomerulonephritis, Membranous D015433 6 associated lipids
Renal Insufficiency D051437 8 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Hyperparathyroidism, Secondary D006962 4 associated lipids
Neuritis D009443 4 associated lipids
Hypertension, Portal D006975 12 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Hepatitis C D006526 7 associated lipids
Lichen Planus D008010 3 associated lipids
Sclerosis D012598 5 associated lipids
Atherosclerosis D050197 85 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Insulin Resistance D007333 99 associated lipids
Liver Failure, Acute D017114 11 associated lipids
Diabetes Complications D048909 4 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Dental Pulp Calcification D003784 2 associated lipids
Hepatitis C, Chronic D019698 12 associated lipids
Coronary Stenosis D023921 6 associated lipids
Dehydration D003681 11 associated lipids
Hemophilia A D006467 10 associated lipids
Encephalitis D004660 15 associated lipids
Dyslipidemias D050171 7 associated lipids
Fatigue D005221 10 associated lipids
Meningoencephalitis D008590 4 associated lipids
Gynecomastia D006177 6 associated lipids
Thyroiditis, Autoimmune D013967 9 associated lipids
Myxedema D009230 2 associated lipids
Pregnancy Complications D011248 19 associated lipids
Candidiasis, Oral D002180 11 associated lipids
Stomatitis D013280 14 associated lipids
Biliary Tract Neoplasms D001661 7 associated lipids
Lung Diseases, Interstitial D017563 5 associated lipids
Weight Loss D015431 56 associated lipids
Tinea D014005 5 associated lipids
Critical Illness D016638 13 associated lipids
Endotoxemia D019446 27 associated lipids
Neoplasm Invasiveness D009361 23 associated lipids
Memory Disorders D008569 33 associated lipids
Glucose Intolerance D018149 13 associated lipids
Dry Eye Syndromes D015352 10 associated lipids
Thinness D013851 11 associated lipids
Opportunistic Infections D009894 8 associated lipids
Eczema D004485 4 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Vasculitis, Leukocytoclastic, Cutaneous D018366 5 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Lupus Nephritis D008181 8 associated lipids
Telangiectasis D013684 2 associated lipids
Anemia, Iron-Deficiency D018798 6 associated lipids
Parkinsonian Disorders D020734 20 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Waechter F Drug company accused of breaking advertising regulations. 2003 BMJ pmid:12763970
Lapsley P Itching for a solution. 2005 BMJ pmid:15731120
Ashcroft DM et al. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. 2005 BMJ pmid:15731121
Misra DP et al. Pulmonary co-infection with Nocardia and Aspergillus in a patient with adult-onset Still's disease receiving steroids and tacrolimus. 2014 BMJ Case Rep pmid:25398925
Slocum AMY A surgeon's nightmare: pyoderma gangrenosum with pathergy effect mimicking necrotising fasciitis. 2017 BMJ Case Rep pmid:29269363
Maus EA The importance of challenging your diagnosis even in straightforward cases. 2012 BMJ Case Rep pmid:22847565
Mallon DH et al. A spontaneous coronary arterial dissection associated with a calcineurin inhibitor. 2012 BMJ Case Rep pmid:22783013
Borges-Costa J et al. Kaposi's sarcoma presenting as violaceous macules on the chest of a kidney transplanted patient. 2016 BMJ Case Rep pmid:26759393
Bonanni A et al. Low-dose ofatumumab for rituximab-resistant nephrotic syndrome. 2015 BMJ Case Rep pmid:26376698
Wu G et al. Tacrolimus-induced encephalopathy and polyneuropathy in a renal transplant recipient. 2013 BMJ Case Rep pmid:24311415
Purani JM and Purani HJ Treatment of geographic tongue with topical tacrolimus. 2014 BMJ Case Rep pmid:25085945
Viecelli A et al. Diagnostic and management dilemma of a pancreas-kidney transplant recipient with aplastic anaemia. 2014 BMJ Case Rep pmid:25257886
Kirpalani A et al. Idiosyncratic drug reactions and membranous glomerulopathy. 2017 BMJ Case Rep pmid:28137906
Liu HY et al. Ribavirin-induced anaemia reduced tacrolimus level in a hepatitis C patient receiving haemodialysis. 2018 BMJ Case Rep pmid:29669765
Gupta M et al. Tacrolimus-induced unilateral ischaemic optic neuropathy in a non-transplant patient. 2012 BMJ Case Rep pmid:22914240
Krystel-Whittemore M et al. Polyomavirus nephropathy of the native kidney in a patient with rheumatoid arthritis and pulmonary fibrosis. 2015 BMJ Case Rep pmid:26318171
Boyer NL et al. Tacrolimus-associated thrombotic microangiopathy in a lung transplant recipient. 2013 BMJ Case Rep pmid:23396921
Undre N and Dickinson J Relative bioavailability of single doses of prolonged-release tacrolimus administered as a suspension, orally or via a nasogastric tube, compared with intact capsules: a phase 1 study in healthy participants. 2017 BMJ Open pmid:28377389
Goldsmith PM et al. Impact of intrapatient variability (IPV) in tacrolimus trough levels on long-term renal transplant function: multicentre collaborative retrospective cohort study protocol. 2017 BMJ Open pmid:28756385
Castillo Lugo JA Clinical and experimental immunosuppression. 1995 May-Jun Bol Asoc Med P R pmid:8573248
Varanasi SS and Datta HK Characterisation of cytosolic FK506 binding protein 12 and its role in modulating expression of Cbfa1 and osterix in ROS 17/2.8 cells. 2005 Bone pmid:15780950
Fukunaga J et al. Expression of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in rat osteoporosis induced by immunosuppressant FK506. 2004 Bone pmid:15003790
Darcy A et al. A novel library screen identifies immunosuppressors that promote osteoblast differentiation. 2012 Bone pmid:22421346
Voggenreiter G et al. Immunosuppression with FK506 has no influence on fracture healing in the rat. 2005 Bone pmid:15963777
Igarashi K et al. Cyclosporine A and FK506 induce osteoclast apoptosis in mouse bone marrow cell cultures. 2004 Bone pmid:15207740
Velasco-Guardado A et al. Potential protective effect of Helicobacter pylori on the development of gastrointestinal GvHD. 2016 Bone Marrow Transplant. pmid:26950379
Cutler C et al. Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. 2011 Bone Marrow Transplant. pmid:20697368
Parody R et al. GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: results of a multicenter study. 2016 Bone Marrow Transplant. pmid:27295268
Hale GA et al. Blood tacrolimus concentrations in bone marrow transplant patients undergoing plasmapheresis. 2000 Bone Marrow Transplant. pmid:10723590
Rotenstein L et al. Management of refractory autoimmune hemolytic anemia via allogeneic stem cell transplantation. 2016 Bone Marrow Transplant. pmid:27272445
Schmook T et al. Treatment of cutaneous chronic graft-versus-host disease with topical pimecrolimus. 2005 Bone Marrow Transplant. pmid:15895116
Boswell GW et al. Tacrolimus pharmacokinetics in BMT patients. 1998 Bone Marrow Transplant. pmid:9486490
Tezcan H et al. Severe cerebellar swelling and thrombotic thrombocytopenic purpura associated with FK506. 1998 Bone Marrow Transplant. pmid:9486505
Ali H et al. Mycophenolate mofetil-based salvage as acute GVHD prophylaxis after early discontinuation of tacrolimus and/or sirolimus. 2015 Bone Marrow Transplant. pmid:25365064
Labrador J et al. Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus. 2014 Bone Marrow Transplant. pmid:24566710
Gharpure VS et al. Thrombotic thrombocytopenic purpura associated with FK506 following bone marrow transplantation. 1995 Bone Marrow Transplant. pmid:8547871
Wingard JR et al. Lack of interaction between tacrolimus (FK506) and methotrexate in bone marrow transplant recipients. 1997 Bone Marrow Transplant. pmid:9232256
Miceli M et al. Significant interaction of tacrolimus with ritonavir during allogeneic hematopoietic SCT in an HIV-infected patient. 2012 Bone Marrow Transplant. pmid:22120984
Yanada M et al. Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Japan. 2004 Bone Marrow Transplant. pmid:15220958
Tam PM et al. Topical 0.03% tacrolimus ointment in the management of ocular surface inflammation in chronic GVHD. 2010 Bone Marrow Transplant. pmid:19802037
Przepiorka D et al. Tacrolimus for prevention of graft-versus-host disease after mismatched unrelated donor cord blood transplantation. 1999 Bone Marrow Transplant. pmid:10414918
Okano A et al. Subcutaneous infection with Mycobacterium fortuitum after allogeneic bone marrow transplantation. 2001 Bone Marrow Transplant. pmid:11704796
Parody R et al. GVHD prophylaxis with sirolimus-tacrolimus may overcome the deleterious effect on survival of HLA mismatch after reduced-intensity conditioning allo-SCT. 2015 Bone Marrow Transplant. pmid:25310306
Takahata M et al. Cyclosporin A-induced encephalopathy after allogeneic bone marrow transplantation with prevention of graft-versus-host disease by tacrolimus. 2001 Bone Marrow Transplant. pmid:11704797
Espino G et al. Assessment of myocardial hypertrophy by echocardiography in adult patients receiving tacrolimus or cyclosporine therapy for prevention of acute GVHD. 2001 Bone Marrow Transplant. pmid:11803349
Watanabe N et al. Relationship between tacrolimus blood concentrations and clinical outcome during the first 4 weeks after SCT in children. 2010 Bone Marrow Transplant. pmid:19915626
Uberti JP et al. Tacrolimus and methotrexate for the prophylaxis of acute graft-versus-host disease in allogeneic bone marrow transplantation in patients with hematologic malignancies. 1997 Bone Marrow Transplant. pmid:9208118
Ohashi Y et al. Successful treatment of steroid-resistant severe acute GVHD with 24-h continuous infusion of FK506. 1997 Bone Marrow Transplant. pmid:9085743
Mehta P et al. Increased clearance of tacrolimus in children: need for higher doses and earlier initiation prior to bone marrow transplantation. 1999 Bone Marrow Transplant. pmid:10627642
Przepiorka D et al. Practical considerations in the use of tacrolimus for allogeneic marrow transplantation. 1999 Bone Marrow Transplant. pmid:10578154
Narimatsu H et al. Short-term methotrexate could reduce early immune reactions and improve outcomes in umbilical cord blood transplantation for adults. 2007 Bone Marrow Transplant. pmid:17115066
Lekakis L et al. Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. 2006 Bone Marrow Transplant. pmid:16892072
Przepiorka D et al. Tacrolimus clearance is age-dependent within the pediatric population. 2000 Bone Marrow Transplant. pmid:11041564
Ganetsky A et al. Higher tacrolimus concentrations early after transplant reduce the risk of acute GvHD in reduced-intensity allogeneic stem cell transplantation. 2016 Bone Marrow Transplant. pmid:26691423
Woo M et al. Toxicities of tacrolimus and cyclosporin A after allogeneic blood stem cell transplantation. 1997 Bone Marrow Transplant. pmid:9466284
Honda A et al. Omission of day-11 MTX, in combination with tacrolimus, is not associated with increased risk of acute graft-versus-host disease after allo-BMT. 2013 Bone Marrow Transplant. pmid:22751000
Khimani F et al. Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention. 2017 Bone Marrow Transplant. pmid:28368376
Fuji S et al. Decreased insulin secretion in patients receiving tacrolimus as GVHD prophylaxis after allogeneic hematopoietic SCT. 2010 Bone Marrow Transplant. pmid:19648969
Onizuka M et al. Cytochrome P450 genetic polymorphisms influence the serum concentration of calcineurin inhibitors in allogeneic hematopoietic SCT recipients. 2011 Bone Marrow Transplant. pmid:21102498
Skeens M et al. Twice daily i.v. bolus tacrolimus infusion for GVHD prophylaxis in children undergoing stem cell transplantation. 2012 Bone Marrow Transplant. pmid:22484323
Hiraoka A et al. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. 2001 Bone Marrow Transplant. pmid:11509936
Yu C et al. Glucocorticoids fail to enhance the effect of FK506 and methotrexate in prevention of graft-versus-host disease after DLA-nonidentical, unrelated marrow transplantation. 1997 Bone Marrow Transplant. pmid:9244417
Fujino M et al. Intestinal thrombotic microangiopathy induced by FK506 in rats. 2007 Bone Marrow Transplant. pmid:17277791
Kakihana K et al. Clinical features of calcineurin inhibitor-induced pain syndrome after allo-SCT. 2012 Bone Marrow Transplant. pmid:21625227
Gaziev D et al. Chronic graft-versus-host disease: is there an alternative to the conventional treatment? 2000 Bone Marrow Transplant. pmid:10745252
Mori T et al. Drug interaction between voriconazole and tacrolimus in allogeneic hematopoietic SCT recipients. 2011 Bone Marrow Transplant. pmid:20453893
Seropian S et al. Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin's lymphoma. 2003 Bone Marrow Transplant. pmid:14520419
Kanamaru A et al. FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. Japanese FK506 BMT Study Group. 1995 Bone Marrow Transplant. pmid:7581086
Koehler MT et al. FK506 (tacrolimus) in the treatment of steroid-resistant acute graft-versus-host disease in children undergoing bone marrow transplantation. 1995 Bone Marrow Transplant. pmid:7581088
Riley L et al. Cross-sensitivity reaction between tacrolimus and macrolide antibiotics. 2000 Bone Marrow Transplant. pmid:10808214
Najera JE et al. Akinetic mutism-a serious complication to tacrolimus-based GVHD prophylaxis. 2013 Bone Marrow Transplant. pmid:22705799
Devine SM et al. Tacrolimus (FK506)-induced cerebral blindness following bone marrow transplantation. 1996 Bone Marrow Transplant. pmid:8879619
Przepiorka D et al. Bronchiolitis obliterans organizing pneumonia in a BMT patient receiving FK506. 1993 Bone Marrow Transplant. pmid:7687503
Trifilio SM et al. Tacrolimus use in adult allogeneic stem cell transplant recipients receiving voriconazole: preemptive dose modification and therapeutic drug monitoring. 2010 Bone Marrow Transplant. pmid:19966844
Ochiai N et al. Successful non-T cell-depleted HLA haplo-identical three-loci mismatched hematopoietic stem cell transplantation from mother to son based on the feto-maternal microchimerism in chronic myelogenous leukemia. 2002 Bone Marrow Transplant. pmid:12439703
Yumura-Yagi K et al. Unrelated donor bone marrow transplantation for 100 pediatric patients: a single institute's experience. 2005 Bone Marrow Transplant. pmid:15968285
Przepiorka D et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. 1999 Bone Marrow Transplant. pmid:10516680
Gondo H et al. Acquired Pelger-Huët anomaly in association with concomitant tacrolimus and fluconazole therapy following allogeneic bone marrow transplantation. 2000 Bone Marrow Transplant. pmid:11149744
Couriel DR et al. Chronic graft-versus-host disease manifesting as polymyositis: an uncommon presentation. 2002 Bone Marrow Transplant. pmid:12379897
Mori T et al. Cold agglutinin disease associated with adenovirus infection after allogeneic bone marrow transplantation. 2005 Bone Marrow Transplant. pmid:15937504
Suehiro A et al. Enhancement by cyclosporine A and tacrolimus of serotonin-induced formation of small platelet aggregation. 2002 Bone Marrow Transplant. pmid:11850703
Uberti JP et al. Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: long-term outcomes. 2004 Bone Marrow Transplant. pmid:15273705
Nelson R et al. Sirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic cell transplantation: a single institution experience. 2015 Bone Marrow Transplant. pmid:26301969
Sastry J et al. Acute pancreatitis due to tacrolimus in a case of allogeneic bone marrow transplantation. 2004 Bone Marrow Transplant. pmid:14743193
Han CW et al. Differential effects of the immunosuppressants cyclosporin A, FK506 and KM2210 on cytokine gene expression. 1995 Bone Marrow Transplant. pmid:7545487
Castagna L et al. Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide. 2016 Bone Marrow Transplant. pmid:26595078
Mookerjee B et al. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. 1999 Bone Marrow Transplant. pmid:10482936
Terakura S et al. Exploratory research for optimal GvHD prophylaxis after single unit CBT in adults: short-term methotrexate reduced the incidence of severe GvHD more than mycophenolate mofetil. 2017 Bone Marrow Transplant. pmid:27941766
Prot-Labarthe S et al. Toxic serum levels of tacrolimus after topical administration in an infant with severe cutaneous graft-versus-host disease. 2007 Bone Marrow Transplant. pmid:17549052
Yanagisawa R et al. Engraftment syndrome, but not acute GVHD, younger age, CYP3A5 or MDR1 polymorphisms, increases tacrolimus clearance in pediatric hematopoietic SCT. 2011 Bone Marrow Transplant. pmid:20383212
Shayani S et al. Aprepitant (Emend) significantly increases sirolimus levels in patients undergoing allogeneic hematopoietic SCT. 2012 Bone Marrow Transplant. pmid:21383680
Zohren F et al. Tacrolimus and mycofenolate mofetil as GvHD prophylaxis following nonmyeloablative conditioning and unrelated hematopoietic SCT for adult patients with advanced hematologic diseases. 2011 Bone Marrow Transplant. pmid:20661230
Perez LE et al. Visilizumab with tacrolimus and methotrexate for GvHD prevention after allogeneic hematopoietic cell transplantation from mismatched unrelated donors. 2017 Bone Marrow Transplant. pmid:27991896
Dvorak CC et al. Use of intravenous mycophenolate mofetil for graft-versus-host disease prophylaxis in an allogeneic hematopoietic stem cell transplant recipient with an allergic reaction to cyclosporine and tacrolimus. 2006 Bone Marrow Transplant. pmid:16785867
Trede NS et al. Tacrolimus (FK506) in allogeneic bone marrow transplantation for severe aplastic anemia following orthotopic liver transplantation. 1997 Bone Marrow Transplant. pmid:9257897
Khaled SK et al. A phase II study of sirolimus, tacrolimus and rabbit anti-thymocyte globulin as GVHD prophylaxis after unrelated-donor PBSC transplant. 2013 Bone Marrow Transplant. pmid:23000644
Nieto Y et al. Acute pancreatitis during immunosuppression with tacrolimus following an allogeneic umbilical cord blood transplantation. 2000 Bone Marrow Transplant. pmid:10918414
Yanik G et al. Tacrolimus (FK506) and methotrexate as prophylaxis for acute graft-versus-host disease in pediatric allogeneic stem cell transplantation. 2000 Bone Marrow Transplant. pmid:10918426
Esquirol A et al. Single-agent GvHD prophylaxis with tacrolimus after post-transplant high-dose cyclophosphamide is a valid option for haploidentical transplantation in adults with hematological malignancies. 2017 Bone Marrow Transplant. pmid:28604667
Cooper MH et al. Short-term myeloid reconstitution following TBI is not adversely affected by doses of FK506 that abrogate lethal GVHD. 1994 Bone Marrow Transplant. pmid:7527689